Gyre Therapeutics (GYRE) News Today → Gold Mania (From Stansberry Research) (Ad) Free GYRE Stock Alerts $14.82 -0.41 (-2.69%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGyre Therapeutics Reports First Quarter 2024 Earningsfinance.yahoo.com - May 11 at 3:33 PMGyre Therapeutics, Inc.: Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updatefinanznachrichten.de - May 10 at 7:14 AMGYRE Stock Earnings: Gyre Therapeutics Reported Results for Q1 2024msn.com - May 10 at 2:14 AMGyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updateglobenewswire.com - May 9 at 4:10 PMNassim Usman Sells 20,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stockinsidertrades.com - May 4 at 5:16 AMPublic companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last weekfinance.yahoo.com - April 27 at 9:23 AMGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.1%marketbeat.com - April 17 at 11:58 AMGyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Timeseekingalpha.com - April 13 at 9:04 AMGyre Therapeutics (NASDAQ:GYRE) Shares Down 9.8% marketbeat.com - April 10 at 3:46 PMGyre therapeutics director Nassim Usman sells shares worth $323,000investing.com - April 5 at 11:50 PMGyre Therapeutics Posts Loss In 2023markets.businessinsider.com - March 26 at 4:39 PMGyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 26 at 6:00 AMRNAZ TransCode Therapeutics, Inc.seekingalpha.com - March 26 at 1:26 AMGyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaumglobenewswire.com - March 21 at 7:00 AMGyre Therapeutics, Inc. (GYRE) stock forecast and price targetfinance.yahoo.com - March 12 at 2:55 PMTVTX Travere Therapeutics, Inc.seekingalpha.com - February 28 at 11:51 PMCantor Fitzgerald Downgrades RAPT Therapeutics (RAPT)msn.com - February 22 at 11:27 PMGyre Therapeutics Incmorningstar.com - December 21 at 11:51 PMGyre Therapeutics Names Han Ying As CEOmarketwatch.com - December 15 at 10:10 PMTotus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Fundingfinance.yahoo.com - December 15 at 12:09 PMGYREseekingalpha.com - December 2 at 11:24 AMGyre Therapeutics Inc GYREmorningstar.com - November 16 at 10:00 AMGyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meetingfinance.yahoo.com - November 13 at 12:03 PMGyre Therapeutics Inc.barrons.com - November 10 at 2:47 PMGyre Therapeutics, Inc. (GYRE)finance.yahoo.com - November 9 at 10:49 AM Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. GYRE Media Mentions By Week GYRE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GYRE News Sentiment▼0.730.58▲Average Medical News Sentiment GYRE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GYRE Articles This Week▼71▲GYRE Articles Average Week Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Ironwood Pharmaceuticals News Today Gemini Therapeutics News Today Belite Bio News Today Collegium Pharmaceutical News Today Prothena News Today MannKind News Today Verona Pharma News Today Spyre Therapeutics News Today Mirum Pharmaceuticals News Today Pacira BioSciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GYRE) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.